| Husain, Shahid |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Completed | N/A | 806 | Europe, Canada, RoW | | University Health Network, Toronto | COVID-19, SARS-CoV 2 | 03/23 | 03/23 | | |
UHN, NCT06344117: Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients |
|
|
| Recruiting | N/A | 45 | Canada | | Owlstone Ltd | Invasive Aspergillosis | 07/25 | 12/25 | | |
NCT05786495: Short Antibiotic Treatment in High Risk Febrile Neutropenia |
|
|
| Recruiting | N/A | 80 | Canada | Early Discontinuation of Antibiotics, Standard of Care | University Health Network, Toronto | Febrile Neutropenia | 12/25 | 02/26 | | |
| Wang, Xin Shelley |
NCT03908138: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma |
|
|
| Recruiting | 4 | 120 | RoW | RDD, RDD group, VDD, VDD group | Shandong Provincial Hospital | Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety | 12/21 | 12/22 | | |
NCT06398834: Esketamine and Butorphanol for Post-Lobectomy Pain |
|
|
| Completed | 4 | 223 | RoW | Esketamine, S-Ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, L-Ketamine, (-)-Ketamine, Butorphanol, Butorphanol Tartrate, Moradol, Stadol, Torbugesic, Apo-Butorphanol, Dolorex | Second People's Hospital of Hefei City, Tongji Hospital | Esketamine, Pain, Post-thoracotomy Pain Syndrome, Thoracic Diseases | 10/23 | 01/24 | | |
NCT04738955: Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors |
|
|
| Recruiting | 4 | 230 | RoW | Micafungin Sodium | Shandong Provincial Hospital | Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | 01/23 | 10/23 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 |
|
|
| Recruiting | 3 | 2 | RoW | SIB-IMRT, Paclitaxel, Platinum-Based Drug, Involved Field Irradiation (IFI) | Chinese Academy of Medical Sciences | IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer | 08/21 | 12/22 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
NCT03978364: A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC |
|
|
| Recruiting | 3 | 100 | RoW | Azacitidine combined HHT, Azacitidine+HHT, Azacitidine regimen, Azacitidine group | Shandong Provincial Hospital | Myelodysplastic Syndromes,Acute Myeloid Leukemia | 06/22 | 12/22 | | |
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX | Shandong Provincial Hospital | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/24 | | |
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies | Shandong Provincial Hospital | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma | 12/23 | 12/24 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT04821843: Neoadjuvant Treatment Modalities in Esophageal Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay, Surgery, Immunotherapy, 5-FU Analog based chemotherpay, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer | 12/25 | 12/25 | | |
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect | 12/25 | 12/25 | | |
NCT05406882: The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis |
|
|
| Recruiting | 2/3 | 176 | RoW | Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules, Probiotics、Glutamine | West China Hospital | Radiation Proctitis, Probiotics, Glutamine, Gut Microbiota, Bifidobacterium | 04/24 | 09/24 | | |
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer |
|
|
| Completed | 2 | 55 | RoW | Radiotherapy, Nimotuzumab, S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm | 12/22 | 06/23 | | |
Rvision-001, NCT04147728: Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Anlotinib, Antiangiogenic agents, Stereotactic Radiosurgery | Peking University Third Hospital, Huashan Hospital, Tianjin Medical University | Stereotactic Body Radiation Therapy | 12/21 | 12/22 | | |
NCT04547452: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC |
|
|
| Recruiting | 2 | 84 | RoW | Stereotactic body radiation therapy, SBRT, Anti-PD-1 antibody drug named Sintilimab | West China Hospital | Stage IV HCC, Immunotherapy, SBRT | 07/22 | 07/23 | | |
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients |
|
|
| Recruiting | 2 | 55 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, AK104 | Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Urothelial Carcinoma | 09/24 | 04/26 | | |
NCT04821765: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel, Cisplatin | Chinese Academy of Medical Sciences | Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy | 09/23 | 09/23 | | |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 186 | RoW | Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene | Locally Advanced Rectal Cancer | 03/24 | 09/29 | | |
NCT06334367: Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT |
|
|
| Not yet recruiting | 2 | 40 | RoW | CD25 treatment, low-dose ATG | Wang Xin | GVHD | 03/26 | 03/26 | | |
| Recruiting | 2 | 90 | RoW | Tislelizumab (BGB-A317) with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 12/26 | 12/27 | | |
NCT06421376: Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy, Surgery | 12/26 | 12/27 | | |
NCT05490485: Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab, cisplatin | Henan Cancer Hospital | Squamous Cell Carcinoma of the Skin | 07/24 | 07/24 | | |
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Chidamide Tablets combined with AK112, AK112 | Shanxi Province Cancer Hospital | Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone | 12/24 | 12/24 | | |
NCT06074484: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, Disitamab Vedotin, AK104, Cadonilimab Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | Muscle Invasive Bladder Carcinoma | 08/24 | 08/25 | | |
NCT06642545: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin, RC48, RC148, Albumin-bound Paclitaxone, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 10/26 | 10/27 | | |
NCT05430737: A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer |
|
|
| Recruiting | 2 | 60 | RoW | stereotactic body radiotherapy | West China Hospital | Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy, Safety | 06/25 | 06/25 | | |
NCT06123455: Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen | Tang-Du Hospital | Gastric Cancer | 07/25 | 07/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
NCT04278287: Chemoradiotherapy in Unresectable Esophageal Cancer |
|
|
| Recruiting | 1/2 | 105 | RoW | Radiotherapy, Albumin-Bound Paclitaxel, Nab-Paclitaxel, Cisplatin, platinum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm | 12/25 | 12/26 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 10/23 | 12/23 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
NCT06344936: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 28 | RoW | HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules | Shandong Suncadia Medicine Co., Ltd. | Chronic Kidney Disease(CKD) | 07/24 | 07/24 | | |
NCT02988921: MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy |
|
|
| Recruiting | N/A | 300 | RoW | MRI and CT, Ratiotherapy, Paclitaxel, platinum-based drug | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer | 01/25 | 12/26 | | |
NCT03247764: A Registration Study on Depression in Patients With Epilepsy |
|
|
| Recruiting | N/A | 320 | RoW | | Shanghai Zhongshan Hospital | Epilepsy, Depression | 12/21 | 01/22 | | |
NCT03902041: The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT |
|
|
| Not yet recruiting | N/A | 160 | RoW | Eltrombopag | Shandong Provincial Hospital | Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag | 04/22 | 10/22 | | |
| Recruiting | N/A | 300 | RoW | Paclitaxel DCB | Beijing Hospital | Coronary Disease | 01/23 | 07/23 | | |
NCT06347965: Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy |
|
|
| Completed | N/A | 104 | RoW | Low load blood flow restriction training, Progressive resistance training group | Xin Wang | Sarcopenia, Lung Neoplasms | 11/23 | 02/24 | | |
NCT06391788: Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy |
|
|
| Recruiting | N/A | 132 | RoW | thoracoscopic Morrow surgery, modified Morrow surgery | China National Center for Cardiovascular Diseases | Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery | 02/25 | 03/25 | | |
NCT04502628: Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT |
|
|
| Recruiting | N/A | 150 | RoW | Hyperbaric oxygen therapy | Shandong Provincial Hospital | Stem Cell Transplant Complications | 07/23 | 12/24 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT04664439: Follow-up With CT-FFR in CHD Patients After DCB |
|
|
| Recruiting | N/A | 92 | RoW | CT-FFR | Beijing Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College | Coronary; Ischemic | 12/23 | 06/24 | | |
NCT05723731: Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation |
|
|
| Terminated | N/A | 106 | RoW | taVNS, Laxative Agent | Air Force Military Medical University, China | Chronic Constipation | 07/23 | 09/23 | | |
NCT05718778: Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma |
|
|
| Recruiting | N/A | 31 | RoW | Piamprimab (AK105), radiotherapy | Henan Cancer Hospital | Soft Tissue Sarcoma | 03/24 | 03/24 | | |
CLL2023, NCT05920668: Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Orelabrutinib | Wang Xin | CLL/SLL | 07/24 | 07/25 | | |
NCT06128252: Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | N/A | 96 | RoW | Taurine, Serplulimab, XELOX regimen, Placebo | Tang-Du Hospital | Gastric Cancer | 06/26 | 06/26 | | |
NCT05934864: Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) |
|
|
| Recruiting | N/A | 1000 | RoW | 84-gene penal | Ruijin Hospital, West China Hospital, Shandong Provincial Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital | Peripheral T Cell Lymphoma | 06/25 | 06/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT04874493: Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer |
|
|
| Active, not recruiting | N/A | 77 | US | Electronic Health Record Review, Questionnaire Administration | M.D. Anderson Cancer Center | Oropharyngeal Carcinoma | 02/27 | 02/27 | | |
NCT00505245: New Assessment System in Measuring Symptom Distress in Cancer Patients |
|
|
| Recruiting | N/A | 6500 | US | Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH) | Caregiver, Health Care Provider, Malignant Neoplasm, Physician | 04/31 | 04/31 | | |
NCT05628480: Multi-omics Analyses Reveal Microbiota-gut-brain Axis in ICU Patients With Post-cardiac Surgery Delirium |
|
|
| Completed | N/A | 60 | RoW | | China National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences | Postoperative Delirium, Cardiac Disease, Gastrointestinal Microbiome | 10/23 | 10/23 | | |
| Yang, Nong |
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 3 | 12000 | RoW | Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed | Hunan Province Tumor Hospital | Lung Cancer | 07/25 | 09/27 | | |
NCT05549037: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC |
|
|
| Recruiting | 3 | 210 | RoW | Pembrolizumab, Sintilimab, time-of-day of administration of immunochemotherapy | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 06/26 | 08/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
| Recruiting | 2 | 200 | RoW | BEBT-109 Capsule, KCBT-1083 | BeBetter Med Inc | Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | 12/25 | 06/26 | | |
NCT04951947: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | JS201 combine with Lenvatinib | Hunan Province Tumor Hospital | Small-cell Lung Cancer | 12/24 | 06/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC |
|
|
| Completed | 2 | 40 | RoW | Toripalimab, platinum-based chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
| Recruiting | 2 | 43 | RoW | Anlotinib and Docetaxel | Yongchang Zhang | Non-Squamous Non Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT05001971: Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 73 | RoW | Anlotinib Plus Penpulimab, Anlotinib & Penpulimab | Hunan Cancer Hospital, Fuzhou Pulmonary Hospital of Fujian, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT05584267: Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy |
|
|
| Recruiting | 2 | 140 | RoW | radiotherapy, Chemotherapy + immunotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 11/25 | 12/26 | | |
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK |
|
|
| Recruiting | 2 | 78 | RoW | Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN | Hunan Province Tumor Hospital | ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | 11/26 | 02/27 | | |
NCT02098954: Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers |
|
|
| Recruiting | 2 | 40 | RoW | Gemcitabine platinum combined with erlotinib, Gemzar, Tarceva | Hunan Province Tumor Hospital | Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation | 12/24 | 12/25 | | |
| Recruiting | 2 | 71 | RoW | SHR-1701 Combined With Fluazopalil | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04144569: PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 Combined With Pyrotinib | Yongchang Zhang | HER2 Insertion Mutation Positive Advanced NSCLC | 12/24 | 12/24 | | |
WUKONG-32, NCT06348927: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC |
|
|
| Recruiting | 2 | 52 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/25 | 04/27 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
| Not yet recruiting | 2 | 172 | RoW | Crisugabalin, Pregabalin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neuropathic Pain | 11/26 | 12/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
NCT06109558: The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | LMV-12(HE003), Osimertinib | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer | 12/26 | 07/27 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04675060: Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules |
|
|
| Recruiting | 1 | 12 | RoW | TQ-B3139 capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumors | 03/22 | 03/22 | | |
NCT05337267: Phase I Study of Sintilimab in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 117 | RoW | sintilimab (after the change), sintilimab (before the change) | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Male Subjects | 05/23 | 07/23 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
NCT04890587: A Phase I Study of AL8326 in Advanced Solid Tumor |
|
|
| Recruiting | 1 | 40 | RoW | AL8326 tablets, AL8326 | Advenchen Laboratories Nanjing Ltd. | Advanced Solid Tumors | 12/23 | 12/23 | | |
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 40 | RoW | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT06183762: A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer |
|
|
| Recruiting | N/A | 200 | RoW | No treatment is included in this protocol. | Hunan Province Tumor Hospital | Advanced Lung Cancer | 12/24 | 06/25 | | |
NCT05059951: Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer |
|
|
| Recruiting | N/A | 15000 | RoW | Immune checkpoint inhibitor, Chemotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 03/28 | | |
NCT03647111: Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 120 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT03646994: Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 40 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
